BACKGROUND: To evaluate new psoriasis treatments, clinicians, regulators and pharmaceutical developers require well-accepted, clinically meaningful measures of disease severity. The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice. OBJECTIVE: Characterize a 5-point Investigator's Global Assessment (IGA) tool and evaluate whether it meets the needs for a valid, clinically meaningful measure. METHODS: A 5-point IGA tool was developed with input from regulatory authorities and clinical trial investigators involved with psoriasis drug development and evaluation. Associations between IGA 0/1 responder rates and PASI scores were evaluated using data from two phase 2 studies with the anti-interleukin (IL)-17A monoclonal antibody secukinumab (AIN457) that utilized a similar 6-point IGA. RESULTS: The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis. Whereas IGA/PGA 0/1 responder rates for earlier scales are strongly associated with PASI 75, the IGA 0/1 rate for the secukinumab 6-point scale was more robust, demonstrating a strong association with PASI 90, and the results for the 5-point IGA are expected to show the same association. DISCUSSION: The 5-point IGA is a valid measure of disease severity and meets the need for a clinically meaningful measure of success for psoriasis treatment studies.
BACKGROUND: To evaluate new psoriasis treatments, clinicians, regulators and pharmaceutical developers require well-accepted, clinically meaningful measures of disease severity. The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice. OBJECTIVE: Characterize a 5-point Investigator's Global Assessment (IGA) tool and evaluate whether it meets the needs for a valid, clinically meaningful measure. METHODS: A 5-point IGA tool was developed with input from regulatory authorities and clinical trial investigators involved with psoriasis drug development and evaluation. Associations between IGA 0/1 responder rates and PASI scores were evaluated using data from two phase 2 studies with the anti-interleukin (IL)-17A monoclonal antibody secukinumab (AIN457) that utilized a similar 6-point IGA. RESULTS: The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis. Whereas IGA/PGA 0/1 responder rates for earlier scales are strongly associated with PASI 75, the IGA 0/1 rate for the secukinumab 6-point scale was more robust, demonstrating a strong association with PASI 90, and the results for the 5-point IGA are expected to show the same association. DISCUSSION: The 5-point IGA is a valid measure of disease severity and meets the need for a clinically meaningful measure of success for psoriasis treatment studies.
Entities:
Keywords:
IL-17; Investigator’s Global Assessment; Physician’s Global Assessment; Psoriasis Area and Severity Index; secukinumab
Authors: Tomas Mlcoch; Jan Tuzil; Liliana Sedova; Jiri Stolfa; Monika Urbanova; David Suchy; Andrea Smrzova; Jitka Jircikova; Tereza Hrnciarova; Karel Pavelka; Tomas Dolezal Journal: Patient Date: 2018-06 Impact factor: 3.883
Authors: Mark G Lebwohl; Leon H Kircik; Angela Y Moore; Linda Stein Gold; Zoe D Draelos; Melinda J Gooderham; Kim A Papp; Jerry Bagel; Neal Bhatia; James Q Del Rosso; Laura K Ferris; Lawrence J Green; Adelaide A Hebert; Terry Jones; Steven E Kempers; David M Pariser; Paul S Yamauchi; Matthew Zirwas; Lorne Albrecht; Alim R Devani; Mark Lomaga; Amy Feng; Scott Snyder; Patrick Burnett; Robert C Higham; David R Berk Journal: JAMA Date: 2022-09-20 Impact factor: 157.335
Authors: Christopher B Forrest; Julia Schuchard; Cortney Bruno; Sandra Amaral; Elizabeth D Cox; Kathryn E Flynn; Pamela S Hinds; I-Chan Huang; Michael D Kappelman; Jerry A Krishnan; Rajesh B Kumar; Jin-Shei Lai; Amy S Paller; Wanda Phipatanakul; Laura E Schanberg; Kaharu Sumino; Elissa R Weitzman; Bryce B Reeve Journal: J Pediatr Date: 2022-03-02 Impact factor: 6.314
Authors: Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo Journal: Acta Derm Venereol Date: 2021-10-21 Impact factor: 3.875
Authors: Hammad Ali Fadlalmola; Muayad Saud Albadrani; Amal Mohamed Elhusein; Wahieba E Mohamedsalih; Veerabhadra D S Swamy; Daniel Mon Mamanao Journal: Dermatol Res Pract Date: 2021-06-22